Skip to main content
Fig. 5 | Stem Cell Research & Therapy

Fig. 5

From: Development and validation of a novel stem cell subtype for bladder cancer based on stem genomic profiling

Fig. 5

BLCA stem cell subtype immunotherapy response prediction. a SCE_H vs SCE_L sensitive response to PD1 and CTLA4 inhibitors (Benjamini and Hochberg corrected P = 0.036, P = 0.036). b SCE_H vs SCE_M sensitive response to PD1 and CTLA4 inhibitors (Benjamini and Hochberg corrected P > 0.05, P = 0.008). c SCE_M vs SCE_L sensitive response to PD1 and CTLA4 inhibitors (Benjamini and Hochberg corrected P = 0.048, P > 0.05). d Sankey chart showing the distribution of BLCA stem cell subtypes in C1–C6 (C5 was not available for BLCA) and molecular subtypes. BLCA, bladder cancer; SCE_H, high stem cell enrichment; SCE_M, medium stem cell enrichment; SCE_L, low stem cell enrichment

Back to article page

Stem Cell Research & Therapy

ISSN: 1757-6512